News
Fate Therapeutics Initiates Enrollment for Phase 1 Clinical Trial of FT825/ONO-8250
Shares of Fate Therapeutics rise by 13% on announcement of Phase 1 clinical trial enrollment Fate Therapeutics has commenced enrollment for its Phase ...